STAT3 and hepatocellular carcinoma: Inflammation promotes HCC progression by recruiting proinflammatory cytokines and regulatory T lymphocytes, activating downstream STAT3 and NF-κB, and inducing a decline in immune cell and inflammatory cell production, leading to an imbalanced host immune response and subsequently to the loss of response to chemotherapy [40–42].